Colorectal Cancer Diagnostics And Therapeutics Market: Market Size & Forecast 2026

The colorectal cancer diagnostics and therapeutics market spans a wide range of modalities, from traditional endoscopic procedures and laboratory-based stool tests to advanced molecular diagnostics, imaging technologies, and pharmacological treatments including chemotherapy, immunotherapy, and targeted therapies. GLOBOCAN data confirms that colorectal cancer remains among the top cancers globally in both incidence and mortality, underpinning sustained investment in innovation across the care continuum.

• •Market valued at $484.0 billion in 2025 with an 8.87% CAGR expected through 2030
• •Encompasses diagnostics, therapeutics, screening platforms, and AI-assisted clinical tools
• •U.S. colorectal cancer treatment costs alone reach $24.3 billion annually

A primary growth engine is the rising global and regional burden of colorectal cancer, including an alarming increase in early-onset cases among younger populations. Expanded screening initiatives, such as the U.S. Healthy People 2030 goal of reaching 68.3% screening adherence and the CDC's 80% by 2030 target, are creating sustained demand for non-invasive diagnostic products like stool-based DNA methylation assays and FIT testing.

• •Growing incidence of early-onset colorectal cancer globally is expanding the addressable patient population
• •National screening targets and regulatory approvals for non-invasive tests (e.g., multi-target stool DNA assays) are driving adoption
• •Advances in immunotherapy and molecular-targeted drugs are increasing the value and complexity of therapeutic regimens

The market spans diagnostics, including molecular assays, AI-assisted endoscopy, and imaging, and therapeutics covering immunotherapy, targeted agents, and traditional chemotherapy. The United States represents the largest single-country market given its high healthcare spending and ambitious screening targets, while Asia-Pacific markets such as China face rapidly growing inpatient treatment costs driven by population size and aging demographics.

• •U.S. accounts for 11.6% of national cancer treatment spending specifically on colorectal cancer
• •China's inpatient colorectal cancer treatment costs are projected to rise significantly through 2030
• •Non-invasive molecular screening solutions (e.g., DNA methylation assays) are reshaping early-diagnosis segments worldwide

What are the recent trends and outlook?

Artificial intelligence and machine learning are becoming embedded in colorectal cancer workflows, from computer-aided polyp detection during colonoscopy to risk-stratification algorithms that improve screening efficiency. The shift toward earlier and more frequent non-invasive screening, enabled by stool-based DNA methylation and multi-target assays, is expected to continue displacing some invasive procedures while expanding overall market reach.

• •AI-assisted colonoscopy and imaging tools are gaining clinical adoption to reduce missed lesions
• •Non-invasive molecular diagnostics and liquid biopsy technologies are expected to grow significantly
• •The total global economic burden of colorectal cancer, including productivity losses, reaches trillions of dollars, reinforcing long-term market resilience